{"id":83226,"title":"Omega Diagnostics Gp (ODX.L) Positive data for COVID-19 antigen test","publisher":"Share Talk","author":"sharetalk","published":"2021-06-01T06:47:48+00:00","modified":"2021-06-01T06:47:48+00:00","canonical_url":"https://www.share-talk.com/omega-diagnostics-gp-odx-l-positive-data-for-covid-19-antigen-test/","markdown_url":"https://www.share-talk.com/omega-diagnostics-gp-odx-l-positive-data-for-covid-19-antigen-test.md","json_url":"https://www.share-talk.com/omega-diagnostics-gp-odx-l-positive-data-for-covid-19-antigen-test.json","category":"Healthcare","categories":["Healthcare"],"tags":["Abingdon Health","Administration","china","Colin King","COVID-19","David Grouse","diseases","Drug","Food","infectious","Medical","ODX","Omega Diagnostics","Omega Diagnostics Gp","Rapid Test","scientists","Screen4","UK Government","UK-RTC","University of Oxford"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1","format":"news","language":"en-GB","content":"**Positive study data for Mologic COVID-19 lateral flow antigen test**\n\nTest shows high diagnostic accuracy ( specificity and sensitivity) exceeding WHO targets\n\n**Omega (AIM: ODX),** the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the publication of a manuscript entitled: “Accuracy of the Mologic COVID-19 rapid antigen test: a prospective multi-centre analytical and clinical evaluation” which provides positive study data relating to Mologic Ltd’s (‘Mologic’) lateral flow antigen test for COVID-19.\n\nThe study concludes that the Mologic test, which has been commercialized by Omega as the VISITECT® COVID-19 Antigen test , has fulfilled the WHO target diagnostic accuracy with a high sensitivity (93.2%-98.4%) detecting individuals with high viral load infections (Ct<20 and Ct<25).\n\nThe VISITECT® COVID-19 Antigen test provides healthcare professionals with an accurate rapid test for the detection of the nucleoprotein of the SARS-CoV-2 virus in respiratory swabs in 10 minutes.\n\nThe Mologic COVID-19 rapid test was evaluated in a prospective multicentre study across UK sites, where a total of 347 participants were enrolled. The Diagnostic accuracy and clinical performance of the test were investigated by comparing to gold standard RT-PCR results from individuals with and without COVID-19 symptoms attending secondary care facilities in Merseyside, ambulance services in Yorkshire, and drive-through testing facilities in Northumberland, UK.\n\nWith data stratified by RT-PCR cycle threshold (Ct), sensitivity was shown to be high in individuals with highest viral loads (i.e. most likely to be highly contagious): 93.2% of samples with a Ct less than 25 and 98.4% of samples with a Ct less than 20. Overall sensitivity (including all cycle thresholds, so individuals with low viral loads as well) and specificity compared to the reference SARS-CoV-2 RT-PCR was 85.0% and 97.8% respectively.\n\nThe study also concluded that the Mologic test replicated diagnostic accuracy in a variety of settings important for COVID-19 control (hospitals, ambulatory services, and drive-through centres) and on self-collected swab specimens. The manuscript can be viewed here: https://wellcomeopenresearch.org/articles/6-132/v1\n\n**Colin King, CEO of Omega, commented:** “This is great news for the Mologic test, which we are now producing under our VISITECT ® brand. It is significant that the test has been shown to have high diagnostic accuracy, but also that this performance is replicated across multiple different settings, different demographics, and on self-collected swab specimens. Rapid diagnostic tests play a crucial role in breaking the spread of infection in the community and we are delighted to be a leading manufacturer of these home-grown tests.”"}